Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Rationale The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.Objectives The purpose of this study was to characterize the pharmacodynamic effects of enadoline, a selective kappa agonist, and to compare it with butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, in humans.Methods Pilot evaluation (n=3) served to establish intramuscular doses of enadoline (20, 40, 80, and 160 microg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity. These acute doses were examined under double-blind, placebo-controlled and constrained randomized conditions with a minimum of 72 h between tests in volunteers with polysubstance abuse histories (n=6). Physiological and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.Results Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output. The highest dose (160 microg/70 kg) was not tolerated and led to psychotomimetic effects. Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria. Butorphanol was most similar to hydromorphone and shared few effects with enadoline.Conclusions These results are discussed with respect to the potential use and safety of kappa agonists for clinical indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A kappa-opioid receptor agonist, enadoline, increased feelings of depersonalization in a small sample of individuals with histories of substance abuse [112].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [112]
Citations
Cites
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857 · cited 3×
“These adverse effects have led some researchers to classify kappa agonists as psychotomimetics ( Pfeiffer et al. 1986 ) and have contributed to the failure of some of these agents in clinical trials.”
BackgroundResultInfluentialInteractions between Kappa Opioid Agonists and Cocaine: Preclinical Studies
Mello, N. K., & Negus, S. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06678.x · Cited by 247
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.
Lamb, R. J., Preston, K. L., Schindler, C. W., Meisch, R. A., Davis, F., Katz, J. L., Henningfield, J. E., & Goldberg, S. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20504-3 · Cited by 245 · cited 1×
“whereby morphine is perceived as dysphoric in drug-naive individuals but euphorigenic in experienced users ( Lamb et al. 1991; Zacny et al. 1994a).”
BackgroundFraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26118-3 · Cited by 232
Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)
Jasinski, D. R. (1977) · Drug Addiction I · doi:10.1007/978-3-642-66612-4_4 · Cited by 200
Hill, J. L., & Zacny, J. P. (2000) · Psychopharmacology · doi:10.1007/s002130000500 · Cited by 195 · cited 2×
“For example, human drug discrimination studies report that the subjective effects of butorphanol are more kappa-like than mu-like (Preston et al. 1989; Preston and Bigelow 1994; see Dykstra et al. 1997 for review) and a direct dosing study suggests that butorphanol can be readily differentiated from a pure mu agonist…”
BackgroundSelectivity of Ligands for Opioid Receptors
Corbett, A. D., Paterson, S. J., & Kosterlitz, H. W. (1993) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-77460-7_26 · Cited by 184 · cited 1×
“Enadoline is a potent compound which binds with high affinity to kappa sites (Ki=0.11 nM) and is estimated to be 900- and 9000-fold more selective for kappa over mu and delta opiate receptors, respectively (Clark et al. 1988; Boyle et al. 1990; Corbett et al. 1993 ).”
BackgroundInfluentialDykstra, L. A., Gmerek, D. E., Winger, G., & Woods, J. H. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39097-x · Cited by 168
Cited by
Items 101–200 of 269
Sherwood, A. M., Crowley, R. S., Paton, K. F., Biggerstaff, A., Neuenswander, B., Day, V. W., Kivell, B. M., & Prisinzano, T. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00148 · Cited by 31
Li, X., Wang, Y., Zhang, M., Wu, W., Kong, L., Ma, Y., Xu, X., Liu, X., Qian, H., Qian, Y., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00857 · Cited by 31
WALSH, S. L., Chausmer, A. E., Strain, E. C., & Bigelow, G. E. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0948-z · Cited by 35
Self-citationMello, N. K., Mendelson, J. H., Sholar, M. B., Jaszyna-Gasior, M., Goletiani, N. V., & Siegel, A. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300631 · Cited by 32
“For example, in men with no history of drug abuse, enadoline, a selective kappa agonist (5–25 mg), produced a number of adverse effects (Reece et al, 1994), whereas in opioid abusers, enadoline in doses up to 80 mg was well tolerated and produced some dysphoria and sedation (Walsh et al, 2001a).”
BackgroundMethodResultInfluentialShram, M. J., Spencer, R. H., Qian, J., Munera, C. L., Lewis, M. E., Henningfield, J. E., Webster, L. R., & Menzaghi, F. (2021) · Clinical and Translational Science · doi:10.1111/cts.13173 · Cited by 30
Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats
Mori, T., Nomura, M., Yoshizawa, K., Nagase, H., Narita, M., & Suzuki, T. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.05.017 · Cited by 30
Denny, L., Abadey, A. A., Robichon, K., Templeton, N., Prisinzano, T. E., Kivell, B. M., & Flamme, A. C. L. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1234 · Cited by 32
“Although these studies indicate that U50,488 is beneficial, it causes undesirable adverse effects including stress, dysphoria, aversion, anxiety, depression, impaired learning, and memory, all of which limit its clinical potential.(12,13) Hence, KOR agonism has the potential to be a very promising target in the treatm…”
BackgroundSu, D., Riley, J., Kiessling, J. W., Armstead, W. M., & Liu, R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318204e029 · Cited by 29
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues
Lee, D. Y. W., He, M., Liu‐Chen, L., Wang, Y., Li, J.-G., Xu, W., Ma, Z., Carlezon, W. A., & Cohen, B. M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.051 · Cited by 31
Aliyev, N. A., & Aliyev, Z. N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820428e1 · Cited by 28
“However, 1 open-label study has found evidence of a role for the opioid receptor antagonist naltrexone in treating dissociative symptoms in the context of borderline personality disorder,(19) and it may be of note that the selective kappa opioid receptor agonist enadoline has been found to induce depersonalization, al…”
BackgroundRetractedMachado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 30
“[9,10] k opiate receptor activation induces depressive symptoms in humans and animals,[11] as well as psychotomimetic effects.[12,13] In preclinical models, the k opioid receptor agonist Salvinorin-A (Salvia divinorum) induced depressive-like behaviors,[14] whereas the receptor antagonist MCL-144B caused antidepressan…”
BackgroundMcDonald, J., & Lambert, D. G. (2014) · BJA Education · doi:10.1093/bjaceaccp/mku041 · Cited by 28
Braida, D., Donzelli, A., Martucci, R., Capurro, V., & Sala, M. (2011) · International Journal of Toxicology · doi:10.1177/1091581811418538 · Cited by 32
The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial
Nielsen, D. A., Hamon, S., & Kosten, T. R. (2013) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000008 · Cited by 27
“Further, KOP-r stimulation in humans is dysphoric (Dykstra et al., 1997; Walsh et al., 2001a, 2001b).”
BackgroundPsychiatric neural networks and neuropharmacology: Selected advances and novel implications
Ghanemi, A. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.01.008 · Cited by 28
“…as a possible medication for mood disorders and, while spiradoline can reduce tics frequency and provoke sedation in patients with Tourette’s Syndrome (Chappell et al., 1993), enadoline can produce sedation, depersonalization, visual distortions, confusion and paranoia (Walsh et al., 2001a,b).”
Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist
Zhou, Y., Freeman, K. B., Setola, V., Cao, D., Kaski, S. W., Kreek, M. J., & Liu‐Chen, L. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_443 · Cited by 30
Cahill, C. M., Tejeda, H. A., Spetea, M., Chen, C., & Liu‐Chen, L. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_433 · Cited by 29
Opioid mechanisms and opioid drugs
McDonald, J., & Lambert, D. G. (2010) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2010.10.008 · Cited by 26
Duke, A. N., Correia, C. J., WALSH, S. L., Bigelow, G. E., & Strain, E. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1898-4 · Cited by 30
“Although the effects of the lower dose of IM hydromorphone (2 mg) were similar to those reported in previous studies (Strain et al. 2000; Walsh et al. 2001), the present effects were not dose-dependent.”
Self-citationBlackburn, K. L., Carr, G. J., Rose, J. L., & Selman, B. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104656 · Cited by 28
Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors
Shu, H., Arita, H., Hayashida, M., Chiba, S., Sekiyama, H., & Hanaoka, K. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.01.004 · Cited by 27
Butelman, E. R., Ball, J., & Kreek, M.-J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1195-y · Cited by 26
“Selective non-peptidic kagonists produce interoceptive and behavioral effects in humans (e.g. sedation, dysphoria and in some cases, psychotomimesis); these effects are dose-related and reversible, and are presumably mediated by k-receptors within the CNS (Pfeiffer et al. 1986a; Rimoy et al. 1994; Walsh et al. 2001).”
BackgroundInfluentialQian, H., Wei, Y., Liu, X., Ye, R., Kong, L., Li, Z., Jiang, S., Yu, L., Chai, J., Xie, Q., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01082 · Cited by 24
The price of seizure control: Dynorphins in interictal and postictal psychosis
Bortolato, M., & Solbrig, M. V. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.11.004 · Cited by 25
“Particularly, clinical investigations on the KOR agonist enadoline have demonstrated its ability to induce depersonalization and sensory misrepresentations (Walsh et al., 2001).”
BackgroundShu, H., Arita, H., Hayashida, M., Sekiyama, H., & Hanaoka, K. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.08.017 · Cited by 24
Recker, M. D., & Higgins, G. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071423 · Cited by 25
“…in humans, and opioid receptor agonists subjective effects generally described as “dysphoric” (Smith and Beecher, 1962; Kumor et al., 1986; Dykstra et al., 1997; Walsh et al., 2001), the available evidence further suggests that ORL-1 receptor agonists may be devoid of such interoceptive properties.”
BackgroundAnalysis of secondary pharmacology assays received by the US Food and Drug Administration
Scott, C. C., Dodson, A., Saulnier, M., Snyder, K., & Racz, R. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107205 · Cited by 25
Prisinzano, T. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400388u · Cited by 29
Atigari, D. V., Uprety, R., Pasternak, G. W., Majumdar, S., & Kivell, B. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.010 · Cited by 23
Valenza, M., Windisch, K. A., Butelman, E. R., Reed, B., & Kreek, M. J. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05444-4 · Cited by 23
Pharmacotherapy of personality disorders
Triebwasser, J., & Siever, L. J. (2007) · Journal of Mental Health · doi:10.1080/09638230601182078 · Cited by 26
“, 1998), depersonalization (Walsh et al., 2001) and psychotomimesis (Pfeiffer et al.”
BackgroundMixed κ/μ Opioid Receptor Agonists: The 6β-Naltrexamines
Cami‐Kobeci, G., Neal, A. P., Bradbury, F. A., Purington, L. C., Aceto, M. D. G., Harris, L. S., Lewis, J. W., Traynor, J. R., & Husbands, S. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8015552 · Cited by 24
Huang, Q., Sun, M., Chen, Y., Li, X., & Wang, Y. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.027 · Cited by 21
“However, direct κ-opioid receptor agonists, particularly the synthetic nonpeptidic agonists, frequently produced serious dysphoric and psychotomimetic adverse effects in humans (Pfeiffer et al., 1986; Preston et al., 2004; Walsh et al., 2001).”
BackgroundAltarifi, A., Yuan, Y., Zhang, Y., Selley, D. E., & Negus, S. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3719-7 · Cited by 24
“However, kappa opioid receptors mediate dysphoric subjective effects and some other undesirable effects (Pfeiffer et al. 1986; Walsh et al. 2001), and kappa-mediated effects may be one factor that limits clinical utility of existing low-efficacy opioids.”
Functional blockage of the cannabinoid receptor type 1 evokes a kappa‐opiate‐dependent analgesia
Sáez-Cassanelli, J. L., Fontanella, G. H., Delgado-Garcia, J. M., & Carrión, Á. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05000.x · Cited by 21
Cyclazocine: comparison to hydromorphone and interaction with cocaine
Preston, K. L., Umbricht, A., Schroeder, J. R., Abreu, M. E., Epstein, D. H., & Pickworth, W. B. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200403000-00001 · Cited by 20
Self-citationShannon, H. E., Eberle, E. L., Mitch, C. H., McKinzie, D. L., & Statnick, M. A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.09.002 · Cited by 20
Behavioral Neurobiology of Bipolar Disorder and its Treatment
Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-15757-8 · Cited by 23
Wu, G., Huang, W., Zhang, H., Li, Q., Zhou, J. F., & Shu, H. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.04.041 · Cited by 21
Wei, Y., Ma, Y., Yao, S.-Y., Kong, L., Liu, X., Chai, J., Chen, J., Li, W., Wang, Y.-J., Shao, L.-M., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00761-x · Cited by 18
“After that, several arylacetamides including enadoline [13, 14] and spiradoline [15] were synthesized and entered into clinical trials for the treatment of pain.”
BackgroundMethodInfluentialDeuis, J. R., Whately, E., Brust, A., Inserra, M. C., Asvadi, N. H., Lewis, R. J., Alewood, P. F., Cabot, P. J., & Vetter, I. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00113 · Cited by 18
Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol
Anderson, R. I., Moorman, D. E., & Becker, H. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_100 · Cited by 19
“Similarly, administration of KOR agonists to humans has been reported to produce aversive effects including anxiety, racing thoughts, agitation, hallucinations, confusion, sedation, and dysphoria (Pfeiffer et al. 1986; Rimoy et al. 1994; Walsh et al. 2001).”
BackgroundDynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry
Tejeda, H. A., Wang, H., Flores, R. J., & Yarur, H. E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_440 · Cited by 19
Stevenson, G. W., Wentland, M. P., Bidlack, J. M., Mello, N. K., & Negus, S. S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.051 · Cited by 20
Low efficacy opioids: Implications for sex differences in opioid antinociception.
Barrett, A. C. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.1.1 · Cited by 20
Treatment of dissociative identity disorder: leveraging neurobiology to optimize success
Purcell, J. B., Brand, B., Browne, H. A., Chefetz, R. A., Shanahan, M., Bair, Z. A., Baranowski, K. A., Davis, V., Mangones, P., Modell, R. L., et al. (2024) · Expert review of neurotherapeutics · doi:10.1080/14737175.2024.2316153 · Cited by 18
“A kappa-opioid receptor agonist, enadoline, increased feelings of depersonalization in a small sample of individuals with histories of substance abuse [111].”
BackgroundJi, M., Yang, J., Gao, Z., Zhang, L., & Liu, C. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.642493 · Cited by 19
Impact of Opioids on Cellular Metabolism: Implications for Metabolic Pathways Involved in Cancer
Tarazi, D., & Maynes, J. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092225 · Cited by 17
“Morphine Natural MOR > DOR > KOR [22,23] Codeine Natural MOR [24] Oxycodone Semi-synthetic MOR > KOR > DOR [25,26] Hydromorphone Semi-synthetic MOR > DOR > KOR [27,28] Buprenorphine Semi-synthetic MOR [29] Hydrocodone Semi-synthetic MOR > KOR > DOR [30] Methadone Synthetic MOR > KOR > DOR [31,32] Fentanyl Synthetic MO…”
Translational value of non-human primates in opioid research
Ding, H., & Ko, M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113602 · Cited by 21
Mori, T., Nomura, M., Yoshizawa, K., Nagase, H., Sawaguchi, T., Narita, M., & Suzuki, T. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.scj05006x · Cited by 17
Heinsbroek, J. A., Furbish, A. B., & Peters, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0006-4 · Cited by 16
“Indeed, the clinical use of KOR agonists in humans has been limited by these known aversive properties [11,12].”
BackgroundDodson, A., Mi, K., Russo, D. P., Scott, C. C., Saulnier, M., Snyder, K., & Racz, R. (2021) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2021.107098 · Cited by 17
Reyes, B. A. S., Chavkin, C., & Bockstaele, E. J. V. (2010) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2010.09.003 · Cited by 17
“Other kOR agonists including enadoline and Cl-977 caused subjects to experience visual distortions, depersonalization, sedation, confusion and abnormal thinking (Walsh et al., 2001; Reece et al., 1994).”
Singh, N., Nolan, T. L., & McCurdy, C. R. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.03.007 · Cited by 16
Li, Z., Ye, R.-F., Qian, H., Lu, J., Sun, Y., Sun, X., Tang, S., Hu, S., Chai, J., Kong, L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02439 · Cited by 14
Townsend, E. A. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05749-9 · Cited by 15
Shu, H., Hayashida, M., Huang, W., An, K., Chiba, S., Hanaoka, K., & Arita, H. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.01.029 · Cited by 16
Ruderman, M. A., Powell, S. B., & Geyer, M. A. (2009) · PubMed · Cited by 15
Margolis, E. B., Wallace, T. L., Orden, L. J. V., & Martin, W. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232864 · Cited by 17
Opioid mechanisms and opioid drugs
McDonald, J., & Lambert, D. G. (2013) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2013.08.002 · Cited by 15
Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2011) · PsycEXTRA Dataset · doi:10.1037/e675632011-001 · Cited by 15
Wallace, T. L., Martin, W. J., & Arnsten, A. F. T. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100493 · Cited by 15
“The KOR system regulates negative emotional states with data from both human and animal studies conferring that KOR activation produces aversive dysphoric-like effects (Carlezon et al., 2006; Land et al., 2009; Pfeiffer et al., 1986; Walsh et al., 2001).”
BackgroundThe Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research
WALSH, S. L., & Babalonis, S. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_448 · Cited by 14
Self-citationPDYN rs2281285 Variant Association with Drinking to Avoid Emotional or Somatic Discomfort
Preuss, U., Winham, S., Biernacka, J., Geske, J., Bakalkin, G., Koller, G., Zill, P., Soyka, M., & Karpyak, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078688 · Cited by 11
“Several lines of evidence have demonstrated that negative feelings and emotions may be related to the dynorphin (DYN)/ kopioid receptor (KOR) system, which may influence the motivational aspects of stress by mediating pro-depressive-like states that involve elements of anhedonia, dysphoria, as well as, pain and aversi…”
BackgroundMathew, S. J., Cutler, A. J., Visitacion, N. C., Gold, M., Yuan, J. X. ‐., & Aurora, B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001967 · Cited by 15
Antinociceptive Effects of Kappa-Opioid Receptor Agonists
Lazenka, M. F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2020_430 · Cited by 14
Liu, X., Jiang, S., Kong, L., Ye, R., Li, X., Xu, X., Qian, H., Wei, Y., Li, Z., Sun, H., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00034 · Cited by 13
Opioid mechanisms and opioid drugs
McDonald, J., & Lambert, D. G. (2016) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2016.06.012 · Cited by 12
van de Wetering, R., Vu, L. Y., Kornberger, L., Luo, D., Scouller, B., Hong, S., Paton, K. F., Prisinzano, T. E., & Kivell, B. M. (2025) · Molecules · doi:10.3390/molecules30030604 · Cited by 13
Chen, C., Huang, P., Bland, K., Li, M., Zhang, Y., & Liu‐Chen, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835809 · Cited by 11
“, 1983) and anti-itch [reviewed in (Inan and Cowan, 2022)] effects; however, they also cause unwanted effects, such as dysphoria, psychotomimetic effects, motor incoordination, and sedation in humans (Pfeiffer et al., 1986; Pande et al., 1996; Walsh et al., 2001; Wadenberg, 2003; MacLean et al., 2013).”
Backgroundvan de Wetering, R., Ewald, A. W. M., Welsh, S., Kornberger, L., Williamson, S. E., McElroy, B. D., Butelman, E. R., Prisinzano, T. E., & Kivell, B. M. (2023) · Molecules · doi:10.3390/molecules28124848 · Cited by 10
Minervini, V., Dahal, S., & France, C. P. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235630 · Cited by 11
“Significant adverse effects of k opioids that preclude their use in the clinic include dysphoria, hallucinations, and diuresis (Pfeiffer et al., 1986; Peters et al., 1987; Walsh et al., 2001).”
BackgroundIusupov, I. R., Lukyanenko, E. R., Altieri, A., & Kurkin, A. V. (2022) · ChemMedChem · doi:10.1002/cmdc.202200394 · Cited by 11
Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles
Ioja, E., Tourwé, D., Kertész, I., Tóth, G., Borsodi, A. D., & Benyhe, S. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.05.010 · Cited by 14
Bakare, T. T., Uzoeto, H. O., Gonlepa, L. N., Cosmas, S., Ajima, J. N., Arazu, A. V., Ezechukwu, S. P., Didiugwu, C. M., Ibiang, G. O., Osotuyi, A. G., et al. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03207-1 · Cited by 14
“The descending inhibitory control route includes the NRM ’ s output, which suppresses nociceptive transmission at the spinal cord level [4, 24].”
Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders
SANTOS, R. G. D., Crippa, J. A. S., Machado‐de‐Sousa, J. P., & Hallak, J. E. C. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107122741 · Cited by 10
“As κ agonists control dopaminergic transmission, these compounds also interact with psychostimulants [19-54].”
BackgroundInfluentialLee, D. Y. W., Deng, G., Ma, Z., Xu, W., Yang, L., Liu, J., Dai, R., & Liu‐Chen, L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.092 · Cited by 10
Clark, S. D. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_396 · Cited by 11
Chiba, S., Hayashida, M., Yoshikawa, M., Shu, H., Nishiyama, T., & Yamada, Y. (2009) · Journal of Anesthesia · doi:10.1007/s00540-008-0697-0 · Cited by 10
Maguire, D. R., & France, C. P. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000184 · Cited by 10
“…of other drugs, including agonists acting at other opioid receptors. κ-Opioid receptor agonists such as spiradoline, a potent congener of U50488, have antinociceptive effects (VonVoigtlander and Lewis, 1988), but their use is precluded by adverse effects (Pfeiffer et al., 1986; Walsh et al., 2001).”
BackgroundHusbands, S. M. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.12.1725 · Cited by 11
“A separate study of enadoline in humans confirmed its unwanted side effects, including psychotomimetic effects at the highest dose evaluated [13].”
BackgroundShao, R., Wang, H., Ruan, Z., Jiang, B., Yang, D., Hu, Y., Xu, Y., Yang, J., Gao, W., Zhao, W., et al. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14094 · Cited by 9
“Early KOR agonists, 13 including U-50488, 14 ICI 199441, 15 spiradoline (U-6266E) 16 and enadoline, 17 were primarily central-selective agents.”
van de Wetering, R., Bibi, R., Biggerstaff, A., Hong, S., Pengelly, B., Prisinzano, T. E., Flamme, A. C. L., & Kivell, B. M. (2024) · Glia · doi:10.1002/glia.24583 · Cited by 9
“…which limit their therapeutic potential (Bals-Kubik et al., 1993; Dalefield et al., 2022; Ehrich et al., 2015; Hasebe et al., 2004; Mague et al., 2003; Mello & Negus, 2000; Mores et al., 2019; Mori et al., 2004; Nagase et al., 1998; Suzuki et al., 1992; Todtenkopf et al., 2004; Walsh et al., 2001).”
Butelman, E. R., Baynard, C., McElroy, B. D., Prisinzano, T. E., & Kreek, M. J. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121996883 · Cited by 8
“These regions can mediate an array of motivational, emotional and executive functions, consistent with some of the reported effects of κ-receptor activation in humans and animal models (Butelman et al., 2012; Carlezon et al., 2006; Nemeth et al., 2010; Walsh et al., 2001; Zhang et al., 2005).”
BackgroundAdvancements in neuroactive peptides in seizures
Јаnkovic, S., & Đešević, M. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2031983 · Cited by 8
“In a clinical trial safety of enadoline was compared with that of butorphanol and hydromorphone; sedation, confusion, dizziness, visual distortions, and feelings of depersonalization were more intense with enadoline [38], and its further development”
BackgroundBorderline personality disorder - a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C. G., Falkai, P., & Wedekind, D. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)72713-4 · Cited by 8
“Dissociation, derealization, and depersonalization are possibly mediated by a dysregulation of -opioid receptors, as agonists at these receptors may cause depersonalization (Pfeiffer, Brantl, Herz, & Emrich, 1986; Walsh et al., 2001).”
BackgroundThe Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs
Mori, T., & Suzuki, T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_29 · Cited by 8
“On the other hand, the k-opioid receptor agonist spiradoline causes sedation and dysphoria but no euphoria [31], whereas enadoline induces feelings of depersonalization in humans [32].”
BackgroundProspects of a Search for Kappa-Opioid Receptor Agonists with Analgesic Activity (Review)
Зайцева, Н. И., Галан, С. Е., & Pavlova, L. A. (2018) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-018-1703-y · Cited by 8
Opioid mechanisms and opioid drugs
McDonald, J. F., & Lambert, D. G. (2007) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2007.10.007 · Cited by 8
Opioid κ Receptors as a Molecular Target for the Creation of a New Generation of Analgesic Drugs
Grechko, O. Y., Спасов, А. А., & Штарёва, Д. М. (2016) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-016-1388-z · Cited by 7
Zhou, Y., Liang, Y., & Kreek, M. J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172954 · Cited by 7
Malcolm‐Smith, S., Thomas, K. G. F., Ipser, J., Stein, D. J., van Honk, J., & Solms, M. (2013) · Neuropsychoanalysis · doi:10.1080/15294145.2013.10799826 · Cited by 7
Niu, Z., Brutiu, B. R., Riomet, M., Kaiser, D., & Maulide, N. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202503750 · Cited by 6
KOR agonists for the treatment and/or prevention of opioid use disorder and cocaine use disorder
Liu‐Chen, L., & Huang, P. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174056 · Cited by 6
Kappa opioid receptor control of motivated behavior revisited
Farahbakhsh, Z. Z., & Siciliano, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02226-9 · Cited by 10
“Right: data were adapted from Walsh et al. 2001 [237].”
InfluentialButorphanol induces anxiety-like behaviour and distress in piglets
Pavlovsky, V. H., Corona, D., Hug, P. J., Kümmerlen, D., Graage, R., & Bettschart‐Wolfensberger, R. (2021) · Schweizer Archiv für Tierheilkunde · doi:10.17236/sat00309 · Cited by 8
Correa, R., Rodriguez, N., & Bortolaso, M. (2021) · European Journal of Trauma & Dissociation · doi:10.1016/j.ejtd.2021.100227 · Cited by 6
Kitamura, T., Ogawa, M., & Yamada, Y. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181a2b5e8 · Cited by 6
Emerging drug for diarrhea predominant irritable bowel syndrome
Deiana, S., Gabbani, T., Bagnoli, S., & Annese, V. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1013935 · Cited by 6
“When k-opioid agonists penetrate the CNS do not produce side effects of respiratory depression or euphoria, but in contrast promote other undesirable adverse effects such as dysphoria, sedation and dieresis [64].”
BackgroundZhou, Y., Zhou, D. C., & Kreek, M. J. (2020) · Journal of Pharmaceutics & Pharmacology · doi:10.13188/2327-204x.1000032 · Cited by 7
“Classic KOR agonists induce aversion, anxiety-like or depression-like behavior that may be responsible for alcohol seeking or relapse- like drinking or dysphoria in humans [4-7].”
Background
Metadata
- Authors
- Walsh, S., Strain, E., Abreu, M., & Bigelow, G.
- Affiliations
- Johns Hopkins University (US)
- AstraZeneca (United States) (US)
- Venue
- Psychopharmacology
- Published
- 2001-09-01
- Volume
- 157
- Issue
- 2
- Pages
- 151-162
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2148208755
- Cited by
- 258
- References
- 51
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 19 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 14 · 2014: 6 · 2013: 15 · 2012: 10
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- National Institute on Drug Abuse (K05DA000050, K05 DA00050, T32-DA07209, R01 DA10753, R01DA010753, T32DA007209)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- kappa opioid receptor agonists, butorphanol, hydromorphone, opioid pharmacodynamics, sedation, psychotomimetic effects, respiratory depression, polysubstance abuse, opioid analgesics, drug safety
- MeSH terms
- Adult, Analgesics, Opioid, Analysis of Variance, Benzofurans, Butorphanol, Hydromorphone, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heroin Dependence, Humans, Male, Middle Aged, Pilot Projects, Pyrrolidines, Receptors, Opioid, kappa, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.